Branded Legacy, Inc. Enhances Capabilities with New Facility
Branded Legacy, Inc. (OTC: BLEG), a leading company in biotechnology focused on innovative addiction treatment and harm reduction solutions, is making impactful strides by acquiring a state-of-the-art facility in Vancouver. This new location is part of BioLegacy Evaluative Group, which represents a significant step in their commitment to combatting the ongoing opioid crisis.
A Strategic Acquisition for Future Growth
This purchase of a 22,000-square-foot property not only strengthens Branded Legacy's infrastructure but also enhances their capabilities to develop essential technologies that save lives. With a fully compliant Good Manufacturing Practices (GMP) facility, BioLegacy is poised to advance its mission effectively, maintaining the highest quality standards in developing solutions aimed at addiction treatment.
Transforming Health Innovation
Following the recent acquisition of BioLegacy Evaluative Group, this new site symbolizes a pivotal advancement in health innovation. Branded Legacy is fostering partnerships with educational institutions like McMaster University and Stanford University to engage in groundbreaking clinical research. These partnerships are crucial in driving forward-thinking strategies in addiction treatment.
High Standards for Quality Control
The new facility is equipped with International Organization for Standardization (ISO) Class 7 and 8 clean rooms, which are crucial in pharmaceutical product development. These environments ensure that the production processes meet stringent particle limits and the highest quality standards, vital for cultivating safe and effective health solutions.
Dedicated to Safety and Compliance
BioLegacy's in-house laboratory is engineered to handle various substances, including opioids, which allows for the safe development of technology tailored to high-risk applications. Furthermore, the company possesses active applications pending for Controlled Substances Licenses with Health Canada, emphasizing their commitment to regulatory compliance and ethical practices.
Local Impact Through Proximity
Situated in the heart of Vancouver, amidst the ongoing drug crisis, the new facility allows for direct collaboration between BioLegacy's experts and the local populations affected by addiction. This unique positioning ensures that their development efforts are informed by real-world challenges, enhancing the potential impact of their solutions against the opioid epidemic.
Leadership's Commitment to Change
Dr. Kristian Thorlund, the Executive Chair at Branded Legacy, articulated the importance of this facility, stating that addressing the opioid epidemic requires the production of devices that can be safely used to mitigate the risks associated with hazardous materials. This acquisition opens up enormous scientific opportunities, enabling new developments in addiction treatment.
Summary and Vision for the Future
Amin Janmohomad, the CEO of Branded Legacy, highlighted the strategic nature of this acquisition by stating that it aligns perfectly with their vision to create a comprehensive ecosystem for addiction solutions. This advanced manufacturing hub, coupled with BioLegacy's expertise and esteemed academic collaborations, positions Branded Legacy as a leader in not just responding to, but actively transforming the landscape of addiction treatment.
About Branded Legacy, Inc.
Branded Legacy, Inc. (OTC: BLEG) is a forward-thinking holdings company focused on health and wellness. They develop innovative solutions aimed at combating addiction and supporting recovery efforts. One of their flagship products, a patented intranasal naloxone delivery device, plays a critical role in enhancing accessibility and precision for opioid overdose treatment, while also paving the way for advancements in vaccine delivery.
For inquiries, investors can contact Branded Legacy, Inc. directly at info@brandedlegacy.com or call 877-250-9077.
Frequently Asked Questions
What is Branded Legacy, Inc. known for?
Branded Legacy, Inc. specializes in developing innovative healthcare solutions focused on addiction treatment and harm reduction.
What facilities has Branded Legacy acquired recently?
They recently acquired a state-of-the-art GMP facility in Vancouver to enhance their production capabilities.
How does the new facility improve their operations?
The facility’s compliance with GMP and ISO standards ensures high-quality production, particularly for sensitive pharmaceuticals.
Who are Branded Legacy's partners?
They have formed strategic partnerships with McMaster University and Stanford University to conduct revolutionary clinical research.
How can investors contact Branded Legacy?
Investors can reach out via email at info@brandedlegacy.com or call 877-250-9077 for any inquiries.
